Baseline characteristics of aerosol cyclosporin (AC) cases and Pittsburgh and multicentric control groups
| Cases | Controls | |||
| Total | AC after BO# | Pittsburgh | Multicentric | |
| Females/males n | 24/15 | 18/8 | 31/20 | 46/54 |
| Indication for transplantation | ||||
| Emphysema | 9 (23) | 4 (15) | 22 (43) | 36 (36) |
| Cystic fibrosis | 10 (26) | 8 (31) | 6 (11) | 20 (20) |
| Fibrotic lung disease | 11 (28) | 7 (27) | 5 (10) | 13 (13) |
| Primary pulmonary hypertension | 2 (5) | 1 (4) | 8 (16) | 14 (14) |
| Other | 7 (18) | 6 (23) | 10 (20) | 17 (17) |
| Type of transplant | ||||
| Single lung | 19 (49) | 12 (46) | 30 (59) | 50 (50) |
| Double lung | 18 (46) | 13 (50) | 14 (27) | 25 (25) |
| Heart/lung | 2 (5) | 1 (4) | 7 (14) | 25 (25) |
| Bronchiolitis obliterans | ||||
| Age at diagnosis yrs | 40.6±13.3 | 38.8±13.1 | 45.1±13.1 | 43.3±13.2 |
| Time after transplant of diagnosis days | 688±524; 557 (321–820) | 519±388; 460 (260–646) | 844±686; 585 (348–1106) | 616±379; 544 (315–901) |
| FEV1+ % pred | 45±16 | 47±16 | 56±26 | 53±21 |
| Acute rejection events¶ before BO | 4.8±3.0; 4 (4–7) | 3.8±2.2; 3 (2–6) | 3.2±1.9; 3 (2–4) | 1.4±1.5; 1 (0–2) |
| Grade 3 BOS+ | 8 (21) | 4 (15) | 8 (15) | 21 (21) |
| Grade 2 BOS+ | 8 (21) | 6 (23) | 10 (20) | 18 (18) |
| Grade 1 BOS+ | 15 (37) | 10 (39) | 10 (20) | 31 (31) |
| No BOS+ | 8 (21) | 6 (23) | 23 (45) | 30 (30) |
| AC therapy duration weeks | 69.9±66.3 | 71.5±0.7 | NA | NA |
| Time between diagnosis and AC therapy weeks | NA | 36.4±36.1 | NA | NA |
Data are presented as n (%), mean±sd or median (interquartile range)
BO: bronchiolitis obliterans
FEV1: forced expiratory volume in one second
BOS: bronchiolitis obliterans syndrome 41
% pred: per cent predicted
NA: not applicable
#: AC received only after histological confirmation of BO
¶: at least grade 2 acute cellular rejection, i.e. mild rejection typically treated with pulsed methylprednisolone or antithymocyte globulin
+: measured at initiation of AC therapy (cases who received AC only after histological confirmation of BO) or at time of histological diagnosis of BO (controls and all other cases)